Disease- and treatment-associated acquired glucocorticoid resistance

Simple item page
dc.contributor.authorWilkinson, Leghen_ZA
dc.contributor.authorVerhoog, Nicolette J. D.en_ZA
dc.contributor.authorLouw, Annen_ZA
dc.date.accessioned2019-09-19T10:01:05Z
dc.date.available2019-09-19T10:01:05Z
dc.date.issued2018-10-11
dc.descriptionCITATION: Wilkinson, L., Verhoog, N. J. D. & Louw, A. 2018. Disease- and treatment-associated acquired glucocorticoid resistance. Endocrine Connections, 7(12):R328–R349, doi:10.1530/EC-18-0421.en_ZA
dc.descriptionThe original publication is available at https://ec.bioscientifica.comen_ZA
dc.description.abstractENGLISH ABSTRACT: The development of resistance to glucocorticoids (GCs) in therapeutic regimens poses a major threat. Generally, GC resistance is congenital or acquired over time as a result of disease progression, prolonged GC treatment or, in some cases, both. Essentially, disruptions in the function and/or pool of the glucocorticoid receptor α (GRα) underlie this resistance. Many studies have detailed how alterations in GRα function lead to diminished GC sensitivity; however, the current review highlights the wealth of data concerning reductions in the GRα pool, mediated by disease-associated and treatment-associated effects, which contribute to a significant decrease in GC sensitivity. Additionally, the current understanding of the molecular mechanisms involved in driving reductions in the GRα pool is discussed. After highlighting the importance of maintaining the level of the GRα pool to combat GC resistance, we present current strategies and argue that future strategies to prevent GC resistance should involve biased ligands with a predisposition for reduced GR dimerization, a strategy originally proposed as the SEMOGRAM–SEDIGRAM concept to reduce the side-effect profile of GCs.en_ZA
dc.description.urihttps://ec.bioscientifica.com/view/journals/ec/7/12/EC-18-0421.xml
dc.description.versionPublisher's versionen_ZA
dc.format.extent22 pages : illustrationsen_ZA
dc.identifier.citationWilkinson, L., Verhoog, N. J. D. & Louw, A. 2018. Disease- and treatment-associated acquired glucocorticoid resistance. Endocrine Connections, 7(12):R328–R349, doi:10.1530/EC-18-0421en_ZA
dc.identifier.issn2049-3614 (online)
dc.identifier.otherdoi:10.1530/EC-18-0421
dc.identifier.urihttp://hdl.handle.net/10019.1/106496
dc.language.isoen_ZAen_ZA
dc.publisherBioScientificaen_ZA
dc.rights.holderAuthors retain copyrighten_ZA
dc.subjectGlucocorticoids -- Receptorsen_ZA
dc.subjectGlucocorticoidsen_ZA
dc.subjectDisease managementen_ZA
dc.subjectGlucocorticoid resistanceen_ZA
dc.titleDisease- and treatment-associated acquired glucocorticoid resistanceen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
wilkinson_disease_2018.pdf
Size:
1.63 MB
Format:
Adobe Portable Document Format
Description:
Download article
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles (Biochemistry)